← Back to signals
NAMS
NewAmsterdam Pharma Co N.V.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
9.4d↑+21.6%
as of 2026-09-30
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G/A | — | 3.7% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (4)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Viking Global | Andreas Halvorsen | 4.2M | $142M |
| Maverick Capital | Lee Ainslie | 3.3M | $111M |
| Duquesne Family Office | Stanley Druckenmiller | 3.1M | $104M |
| Point72 | Steve Cohen | 169K | $6M |
Quarter-end 13F positions for the tracked funds holding this stock.